Everything you need to know about the decision on who should be screened for prostate cancer ...

PSA stands for prostate-specific antigen, a substance naturally produced in prostate tissue. A small amount of PSA regularly sneaks into the bloodstream, and low blood concentration is considered ...

The recent FDA approval of the IsoPSA blood test may represent a notable advancement in prostate cancer screening and diagnosis. Developed by Cleveland Diagnostics, the in vitro diagnostic instrument ...

Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...

We have made important advancements in treatment, but are still being overwhelmed by the number of late-stage cases ...

Prostate cancer incidence is predicted to double to 2·9 million cases by 2040. Men diagnosed with clinically significant prostate cancer have many effective treatment options, but questions remain ...

It recommends that only men with a confirmed genetic risk of prostate cancer should be screened for the disease.

The UK National Screening Committee (UK NSC) has rejected calls for population-wide prostate cancer screening using the PSA ...

In a recent interview with CURE, Dr. Kai Tsao broke down current treatment advancements for patients with prostate cancer.

A new 40-year study (1984-2023) of about a half-million prostate cancer cases – including 150,000 prostate cancer deaths – by the University of Ottawa, in conjunction with Stats Can, shows an alarming ...

Rather, the UK National Screening Committee (NSC) has recommended a targeted approach, only for men with a confirmed BRCA1 or ...